Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.
The dose of combination chemotherapy in Hodgkin's disease is commonly calculated from a formula based on the body surface area. A method is described for measuring the intensity of combination chemotherapy actually received compared to the calculated planned dose. The technique is applied to 56 patients receiving mustine, vinblastine, procarbazine and prednisolone, but would also be suitable for other cytotoxic regimens. The planned dosage intensity had to be significantly reduced in over half of the patients because of marrow toxicity. Splenectomized patients received a higher dose intensity than those in whom the procedure was not performed.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D001830:Body Surface Area; D001855:Bone Marrow Diseases / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage*; D011239:Prednisolone / Q000008:administration & dosage* / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage* / Q000009:adverse effects; D013156:Splenectomy; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014747:Vinblastine; D011239:Prednisolone